- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan
![AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan AstraZeneca gets CDSCO panel nod to study anticancer drug Datopotamab deruxtecan](https://medicaldialogues.in/h-upload/2022/10/28/750x450_189158-astrazeneca-new-1.webp)
New Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct Phase III clinical trial of the anticancer drug Datopotamab deruxtecan.
This came after the drug major AstraZeneca presented Phase III clinical trial protocol no D926NC, version 1.0 dated 15-07-2022, local clinical trial protocol addendum IND-1, version 1.0 dated 11-08-2022 before the committee.
Datopotamab deruxtecan, an antibody-drug conjugate directed against trophoblast cell surface antigen-2 (Trop-2), is showing promise as a treatment for relapsed or refractory advanced triple-negative breast cancer.
Datopotamab deruxtecan is an antibody-drug conjugate with three components: a humanized anti–Trop-2 IgG1 monoclonal antibody attached to a topoisomerase 1 inhibitor payload via a tetrapeptide-based cleavable linker. It was designed with these key attributes: topoisomerase 1 inhibition as the payload mechanism of action; a payload with high potency, short systemic half-life, and stable linker; optimized drug-to-antibody ratio; tumour-selective cleavable linker; and bystander antitumor effect,
At the recent SEC meeting for oncology and hematology held on December 9th 2022, the expert panel reviewed the Phase III clinical trial protocol of the anticancer drug Datopotamab Deruxtecan (Dato-DXD).
After detailed deliberation, the committee recommended the grant of permission to conduct the study of the anticancer drug Datopotamab deruxtecan.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Next Story